Slide background
Certifico: Informazione tecnica HSE / 25° anno

/ Documenti disponibili: 43.745
/ Totale documenti scaricati: 30.913.554

Vedi Abbonamenti, Prodotti tecnici e Software 2025

* Dati in real-time da Aprile 2014 alla data odierna.
 
Slide background
Slide background
Certifico 2000/2024: Informazione Utile




/ Documenti disponibili: 43.745 *

/ Totale documenti scaricati: 30.913.554 *

Vedi Abbonamenti, Prodotti e Software 2024


* Dati in real-time da Aprile 2014 alla data odierna.
Slide background
Certifico 2000/2024: Informazione Utile

/ Documenti disponibili: 43.745 *

/ Totale documenti scaricati: 30.913.554 *

Vedi Abbonamenti Promo 2023


* Dati in real-time da Aprile 2014 alla data odierna.
Slide background
Slide background
Certifico 2000/2023: Informazione Utile

/ Documenti disponibili: 43.745 *

/ Totale documenti scaricati: 30.913.554 *


Vedi Abbonamenti Promo 2023


* Dati in real-time da Aprile 2014 alla data odierna.
Slide background
Certifico 2000/2023: Informazione Utile

Slide background
Certifico 2000/2023: Informazione Utile

Slide background
Certifico 2000/2023: Informazione Utile

Abbonamenti Promo fino al 20 Agosto - 20% ticket "CERTIFICO20"

Vedi Abbonamenti Promo: 2X, 3X, 4X, Full | 2023
Slide background
Certifico 2000/2023: Informazione Utile

Abbonamenti Promo fino al 20 Agosto - 20% ticket "CERTIFICO20"

Vedi Abbonamenti Promo: 2X, 3X, 4X, Full | 2023
Slide background
Certifico 2000/2023: Informazione Utile

/ Documenti disponibili: 43.745 *

/ Totale documenti scaricati: 30.913.554 *

Vedi Abbonamenti Promo 2023

* Dati in real-time da Aprile 2014 alla data odierna.
Slide background
Certifico 2000/2022: Informazione Utile

/ Documenti disponibili: 43.745 *

/ Totale documenti scaricati: 30.913.554 *


Vedi Abbonamenti Promo 2022

* Dati in real-time da Aprile 2014 alla data odierna.
Slide background
Certifico 2000/2022: Informazione Utile

Tutti i Software, Prodotti e Documenti Tecnici presenti sono elaborati direttamente

o selezionati su Norme Tecniche & Standards riconosciuti.


Vedi Abbonamenti Promo: 2X, 3X, 4X, Full | 2022
Slide background
Certifico 2000/2021: Informazione Utile

Tutti i Software, Prodotti e Documenti Tecnici presenti sono elaborati direttamente

o selezionati su Norme Tecniche & Standards riconosciuti.

Vedi Abbonamenti Promo: 2X, 3X, 4X, Full | 2021








Europe, Rome

EMA recommends Nuvaxovid for authorisation in the EU

ID 15212 | | Visite: 1970 | NewsPermalink: https://www.certifico.com/id/15212

Temi: Coronavirus

EMA recommends Nuvaxovid

EMA recommends Nuvaxovid for authorisation in the EU

EMA, 20/12/2021

EMA approva il vaccino anti Covid di Novavax (Nuvaxovid)

L’EMA, Agenzia europea dei Farmaci ha approvato il vaccino anti Covid di Novavax, società Usa con sede nel Maryland, chiamato Nuvaxovid (NVX-CoV2373). È il quinto vaccino contro il virus del Covid autorizzato in Europa. È indicato dai 18 anni in su. Attualmente è autorizzato in via emergenziale in alcuni Paesi asiatici (Indonesia, Filippine). Il vaccino anti Covid di Novavax è a base di proteine ricombinanti (tecnologia è sperimentata da 30 anni), Efficacia su Omicron non individuata.

EMA has recommended granting a conditional marketing authorisation for Novavax’s COVID-19 vaccine Nuvaxovid (also known as NVX-CoV2373) to prevent COVID-19 in people from 18 years of age.

Nuvaxovid is the fifth vaccine recommended in the EU for preventing COVID-19. It is a protein-based vaccine and, together with the already authorised vaccines, will support vaccination campaigns in EU Member States during a crucial phase of the pandemic.

After a thorough evaluation, EMA’s human medicines committee (CHMP) concluded by consensus that the data on the vaccine were robust and met the EU criteria for efficacy, safety and quality.

Results from two main clinical trials found that Nuvaxovid was effective at preventing COVID-19 in people from 18 years of age. The studies involved over 45,000 people in total. In the first study, around two thirds of participants received the vaccine and the others were given a placebo (dummy) injection; in the other study, participants were equally split between Nuvaxovid and placebo. People did not know if they had been given Nuvaxovid or placebo.

The first study, conducted in Mexico and the United States, found a 90.4% reduction in the number of symptomatic COVID-19 cases from 7 days after the second dose in people who received Nuvaxovid (14 cases out of 17,312 people) compared with people given placebo (63 out of 8,140 people). This means that the vaccine had a 90.4% efficacy in this study.

The second study conducted in the United Kingdom also showed a similar reduction in the number of symptomatic COVID-19 cases in people who received Nuvaxovid (10 cases out of 7,020 people) compared with people given placebo (96 out of 7,019 people); in this study, the vaccine efficacy was 89.7%.

Taken together, the results of the two studies show a vaccine efficacy for Nuvaxovid of around 90%. The original strain of SARS-CoV-2 and some variants of concern such as Alpha and Beta were the most common viral strains circulating when the studies were ongoing. There is currently limited data on the efficacy of Nuvaxovid against other variants of concern, including Omicron.

The side effects observed with Nuvaxovid in the studies were usually mild or moderate and cleared within a couple of days after vaccination. The most common ones were tenderness or pain at the injection site, tiredness, muscle pain, headache, a general feeling of being unwell, joint pain, and nausea or vomiting.

The safety and effectiveness of the vaccine will continue to be monitored as it is used across the EU, through the EU pharmacovigilance system and additional studies by the company and European authorities.

Where to find more information
The product information for Nuvaxovid contains information for healthcare professionals, a package leaflet for members of the public and details of conditions of the vaccine’s authorisation.

An assessment report with details of EMA’s evaluation of Nuvaxovid and the full risk management plan will be published shortly. Clinical trial data submitted by the company in the application for marketing authorisation will be published on the Agency’s clinical data website in due course.

More information is available in an overview of the vaccine in lay language, including a description of the vaccine’s benefits and risks and why EMA recommended its authorisation in the EU.

How Nuvaxovid works
Nuvaxovid works by preparing the body to defend itself against COVID-19. The vaccine contains a version of a protein found on the surface of SARS-CoV-2 (the spike protein), which has been produced in the laboratory. It also contains an ‘adjuvant’, a substance to help strengthen the immune responses to the vaccine.

When a person is given the vaccine, their immune system will identify the protein as foreign and produce natural defences — antibodies and T cells — against it. If, later on, the vaccinated person comes into contact with SARS-CoV-2, the immune system will recognise the spike protein on the virus and be prepared to attack it. The antibodies and immune cells can protect against COVID-19 by working together to kill the virus, prevent its entry into the body’s cells and destroy infected cells.

Nuvaxovid is given as two injections, usually into the muscle of the upper arm, 3 weeks apart.

Conditional marketing authorisation
The European Commission will now fast-track the decision-making process to grant a decision on the conditional marketing authorisation for Nuvaxovid, allowing this vaccine to be included in vaccination programmes rolled out across the EU.

Conditional marketing authorisation (CMA) is used as the fast-track authorisation procedure to speed up approval of treatments and vaccines during public health emergencies in the EU. CMAs allow authorisation of medicines that fulfil an unmet medical need on the basis of less complete data than normally required. This happens if the benefit of a medicine or vaccine’s immediate availability to patients outweighs the risk inherent in the fact that not all the data are yet available.

A CMA guarantees that the approved medicine or vaccine meets rigorous EU standards for efficacy, safety and quality and is manufactured in approved, certified facilities in line with high pharmaceutical standards for large-scale production.

Once a CMA has been granted, companies must provide further data from ongoing or new studies within pre-defined deadlines to confirm that the benefits continue to outweigh the risks.

Monitoring the safety of Nuvaxovid
In line with the EU’s safety monitoring plan for COVID-19 vaccines, Nuvaxovid will be closely monitored and subject to several activities that apply specifically to COVID-19 vaccines. Although large numbers of people have received COVID-19 vaccines in clinical trials, certain side effects may only emerge when millions of people are vaccinated.

Companies are required to provide monthly safety reports in addition to the regular updates required by legislation and conduct studies to monitor the safety and effectiveness of the vaccines as they are used by the public. In addition, independent studies of COVID-19 vaccines coordinated by EU authorities will give more information on the vaccine’s long-term safety and benefit in the general population.

These measures will allow regulators to swiftly assess data emerging from a range of different sources and take any necessary regulatory action to protect public health.

Assessment of Nuvaxovid
During the assessment of Nuvaxovid, CHMP had the support of EMA’s safety committee, PRAC, who assessed the risk management plan of Nuvaxovid, and the COVID-19 EMA pandemic task force (COVID-ETF), a group that brings together experts from across the European medicines regulatory network to facilitate rapid and coordinated regulatory action on medicines and vaccines for COVID-19.

Collegati

Tags: Coronavirus

Ultimi inseriti

Lug 02, 2025 141

Ordinanza Emilia-Romagna n. 150 del 30 giugno 2025

Ordinanza Emilia-Romagna n. 150 del 30 giugno 2025 / Rischio calore solare lavoro ID 24211 | 02.07.2025 Dal 2 luglio 2025 in Emilia-Romagna ferme le attività tra le ore 12.30 e le 16, nei cantieri edili e affini, in agricoltura, nel florovivaismo e nei piazzali della logistica, quando il livello di… Leggi tutto
Lug 02, 2025 410

Ordinanza Regione Veneto n. 34 del 01 luglio 2025

Ordinanza Regione Veneto n. 34 del 01 luglio 2025 / Rischio calore solare lavoro ID 24210 | 02.07.2025 Ordinanza del Presidente della Giunta regionale n. 34 del 01 luglio 2025 Disposizioni di carattere contingibile e urgente in merito all’attività lavorativa svolta nel settore agricolo e… Leggi tutto
Lug 02, 2025 111

Ordinanza Regione Emilia-Romagna n. 101 del 26 luglio 2024

Ordinanza Regione Emilia-Romagna n. 101 del 26 luglio 2024 / Rischio calore solare lavoro ID 24209 | 02.07.2025 Ordinanza contingibile e urgente per motivi di igiene e sanità pubblica - misure di prevenzione per attività lavorativa nel settore agricolo e florovivaistico nonché nei cantieri edili e… Leggi tutto
EN 17639 2025
Lug 02, 2025 84

EN 17639:2025

EN 17639:2025 / Cableway installations - General safety requirements ID 24207 | 02.07.2025 / Preview attached EN 17639:2025Safety of machinery - Cableway installations designed for the transport of material and specially designated persons - General safety requirements This Type C standard document… Leggi tutto
Protocollo su salute e sicurezza nei luoghi di lavoro Regione Lombardia e Parti Sociali
Lug 01, 2025 203

Protocollo d’intesa su salute e sicurezza nei luoghi di lavoro Regione Lombardia e Parti Sociali

Protocollo d’intesa su salute e sicurezza nei luoghi di lavoro Regione Lombardia e Parti Sociali ID 24204 | 01.07.2025 Il 1° luglio 2025, è stato firmato un protocollo tra Regione Lombardia e Parti Sociali che ha l’obiettivo di prevenire comportamenti elusivi nell’erogazione della formazione in… Leggi tutto
Decreto Legislativo 12 giugno 2025 n  99
Lug 01, 2025 121

Decreto Legislativo 12 giugno 2025 n. 99

in News
Decreto Legislativo 12 giugno 2025 n. 99 / Contrasto bullismo e cyberbullismo ID 24203 | 01.07.2025 Decreto Legislativo 12 giugno 2025 n. 99 Disposizioni in materia di prevenzione e contrasto del bullismo e del cyberbullismo, in attuazione della delega di cui all'articolo 3 della legge 17 maggio… Leggi tutto

Ultimi Documenti Abbonati

EN 17639 2025
Lug 02, 2025 84

EN 17639:2025

EN 17639:2025 / Cableway installations - General safety requirements ID 24207 | 02.07.2025 / Preview attached EN 17639:2025Safety of machinery - Cableway installations designed for the transport of material and specially designated persons - General safety requirements This Type C standard document… Leggi tutto
Programma nazionale di esplorazione mineraria
Lug 01, 2025 197

Programma nazionale di esplorazione mineraria

Programma nazionale di esplorazione mineraria / Approvato 01.07.2025 ID 24201 | 01.07.2025 / In allegato Approvato il Programma nazionale di esplorazione mineraria La problematica della sicurezza nell’approvvigionamento delle risorse minerarie indispensabili per lo sviluppo industriale e la… Leggi tutto